UTHR logo

United Therapeutics (UTHR) Company Overview

Profile

Full Name:

United Therapeutics Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 17, 1999

Indexes:

Not included

Website:

http://www.unither.com

Description:

United Therapeutics Corporation is an American biotechnology company that develops and markets pharmaceuticals for patients with severe chronic diseases. Currently, the company's product portfolio includes four commercial drugs for the treatment of pulmonary arterial hypertension (PAH): Remodulin (treprostinil) - a drug approved by the FDA for subcutaneous and intravenous administration in 2002 and 2004, respectively; Tyvaso (treprostinil) - a drug approved by the FDA in 2009; Orenitram (treprostinil) - the only FDA-approved orally administered analog of prostacyclin; Adcirca (tadalafil) - a PDE-5 inhibitor, with tadalafil as the active pharmaceutical ingredient. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Key Details

Price

$315.91

Market Cap

$14.19 B(Large cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$2.88 B(+23.63% YoY)

Annual EPS

$24.64(+24.38% YoY)

PE Ratio

12.84

Annual ROE

19.23%

Annual Debt To Equity

0.05

Beta

0.39

Events Calendar

Earnings

Next earnings date:

May 1, 2025

Recent quarterly earnings:

Feb 26, 2025

Recent annual earnings:

Feb 26, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sep 23, 2009

Analyst ratings

Recent major analysts updates

Feb 27, 25 HC Wainwright & Co.
Buy
Jan 8, 25 UBS
Buy
Nov 1, 24 Goldman Sachs
Neutral
Oct 31, 24 Oppenheimer
Outperform
Oct 31, 24 Ladenburg Thalmann
Buy
Oct 31, 24 HC Wainwright & Co.
Buy
Oct 31, 24 Argus Research
Buy
Oct 21, 24 TD Cowen
Buy
Sep 23, 24 Jefferies
Buy
Aug 28, 24 Oppenheimer
Outperform

Screeners with UTHR included

US stocks
Stocks below SMA 200
Most recommended stocks
Best performing stocks last 5 years
Stocks below analysts price target
Healthcare sector
All stocks
High Altman Z score stocks
NASDAQ Listed Companies
Companies with buyback

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$315.91
UTHR price is $315.91

Price All-time High

$409.47
UTHR price is currently -22.85% below its historical high of $409.47

Price Analysts Target

$395.00
UTHR price is currently -20.02% lower than the consensus analysts' forecast

Price Most Recent Change

+0.66%
UTHR price was up +0.66% on Mar 7, 2025

Price YTD Change

-12.29%
UTHR price is down -12.29% since January 1st

Price 3-Year Change

+82.77%
UTHR price is up +82.77% over the past 3 years

Market cap

Market Cap

$14.19 B
UTHR market capitalization is $14.19 billion

Market Cap 3-Year Change

+81.87%
UTHR market capitalization is up +81.87% over the past 3 years

Market Cap All-time High

$18.28 B
UTHR market capitalization is currently -22.39% below its historical high of $18.28 billion

Market Cap Sector Rank

94.49%
UTHR market capitalization is higher than 94.49% of companies in Healthcare sector

Technical

Beta

0.39
UTHR beta is 0.39

200-day SMA

$343.87
UTHR price is currently -8.13% below its 200-day simple moving average

14-day RSI

34.44
UTHR 14-day relative strength index is 34.44

30-day Relative Volume

1.44
UTHR 30-day relative volume is 1.44

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$2.88 B
UTHR annual revenue is $2.88 billion

Annual Revenue Analysts Estimate

$3.15 B
UTHR annual revenue is currently -8.63% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+23.63%
UTHR annual revenue is up +23.63% year-on-year

Annual Revenue Sector Rank

88.61%
UTHR annual revenue is higher than 88.61% of companies in Healthcare sector

Profit

Annual Gross Profit

$2.57 B
UTHR annual gross profit is $2.57 billion

Annual Gross Margin

89.24%
UTHR annual gross profit margin is 89.24%

Annual Operating Profit

$1.45 B
UTHR annual operating income is $1.45 billion

Annual Operating Margin

50.33%
UTHR annual operating profit margin is 50.33%

Annual Net Income

$1.20 B
UTHR annual net profit is $1.20 billion

Annual Net Margin

41.53%
UTHR annual net profit margin is 41.53%

EPS

Annual EPS

$24.64
UTHR annual earnings per share is $24.64

Annual EPS Analysts Estimate

$27.27
UTHR annual earnings per share is currently -9.65% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+24.38%
UTHR annual earnings per share is up +24.38% year-on-year

Annual EPS Sector Rank

99.56%
UTHR annual earnings per share is higher than 99.56% of companies in Healthcare sector

ROA & ROE

Annual ROA

16.45%
UTHR annual return on assets is 16.45%

Annual ROE

19.23%
UTHR annual return on equity is 19.23%

EBIT & EBITDA

Annual EBIT

$1.58 B
UTHR annual earnings before interest & taxes is $1.58 billion

Annual EBITDA

$1.65 B
UTHR annual EBITDA is $1.65 billion

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

12.84
UTHR price to earnings ratio is 12.84

PE Ratio Sector Rank

18.23%
UTHR price to earnings ratio is higher than 18.23% of companies in Healthcare sector

PB Ratio

PB Ratio

2.20
UTHR price to book ratio is 2.20

PB Ratio Sector Rank

62.03%
UTHR price to book ratio is higher than 62.03% of companies in Healthcare sector

PS Ratio

PS Ratio

4.93
UTHR price to sales ratio is 4.93

PS Ratio Sector Rank

63.36%
UTHR price to sales ratio is higher than 63.36% of companies in Healthcare sector

Enterprise value

Enterprise Value

$12.79 B
UTHR enterprise value is $12.79 billion

Enterprise Value Sector Rank

93.03%
UTHR enterprise value is higher than 93.03% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

7.73
UTHR EV/EBITDA is 7.73

EV/EBITDA Sector Rank

79.86%
UTHR EV/EBITDA is higher than 79.86% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

5.25
UTHR annual current ratio is 5.25

Annual Quick Ratio

5.03
UTHR annual quick ratio is 5.03

Leverage

Annual Debt To Equity

0.05
UTHR annual debt to equity ratio is 0.05

Annual Interest Coverage Ratio

36.87
UTHR annual interest coverage ratio is 36.87

Risk & Stability

Piotroski F-Score

-
UTHR piotroski f-score value is unknown

Altman Z-Score

12.24
UTHR altman z-score is 12.24

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$7.36 B
UTHR annual total assets is $7.36 billion

Annual Non Current Assets

$3.49 B
UTHR annual long term assets is $3.49 billion

Annual Current Assets

$3.87 B
UTHR annual total current assets is $3.87 billion

Annual Cash & Cash Equivalents

$1.70 B
UTHR annual cash & cash equivalents is $1.70 billion

Equity

Annual Book Value

$6.44 B
UTHR annual book value is $6.44 billion

Annual Working Capital

$3.14 B
UTHR annual working capital is $3.14 billion

Liabilities

Annual Total Liabilities

$920.00 M
UTHR annual total liabilities is $920.00 million

Annual Total Long Term Liabilities

$181.90 M
UTHR annual total long term liabilities is $181.90 million

Annual Current Liabilities

$738.10 M
UTHR annual total current liabilities is $738.10 million

Annual Accounts Payable

$6.00 M
UTHR annual accounts payable is $6.00 million

Debt

Annual Total Debt

$300.00 M
UTHR annual total debt is $300.00 million

Annual Total Debt 1-Year Change

-57.14%
UTHR annual total debt is down -57.14% year-on-year

Annual Long Term Debt

-
UTHR annual long term debt value is unknown

Annual Short Term Debt

$300.00 M
UTHR annual short term debt is $300.00 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$1.43 B
UTHR annual total expenses is $1.43 billion

Annual Operating Expenses

$1.12 B
UTHR annual total operating expenses is $1.12 billion

Annual Cost Of Goods Sold

$309.70 M
UTHR annual cost of goods sold is $309.70 million

Annual SGA

$638.60 M
UTHR annual SGA is $638.60 million

Annual D&A

$72.50 M
UTHR annual depreciation & amortization is $72.50 million

Annual Interest Expense

$42.90 M
UTHR annual interest expense is $42.90 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

$1.33 B
UTHR annual cash flow from operations is $1.33 billion

Annual CFO 1-Year Change

+35.7%
UTHR annual cash flow from operations is up +35.7% year-on-year

Annual CFI

$417.20 M
UTHR annual cash flow from investing activities is $417.20 million

Annual CFI 1-Year Change

+157.98%
UTHR annual cash flow from investing activities is up +157.98% year-on-year

Annual CFF

-$1.25 B
UTHR annual cash flow from financing activities is -$1.25 billion

Annual CFF 1-Year Change

-10444.54%
UTHR annual cash flow from financing activities is down -10444.54% year-on-year

Free CashFlow

Annual FCF

$1.08 B
UTHR annual free cash flow is $1.08 billion

Annual FCF 1-Year Change

+44.54%
UTHR annual free cash flow is up +44.54% year-on-year

CAPEX

Annual CAPEX

$246.50 M
UTHR annual capital expenditures is $246.50 million

Annual CAPEX 1-Year Change

+6.99%
UTHR annual capital expenditures is up +6.99% year-on-year

Institutional Ownership

Similar stocks

RVTY logo
Revvity (RVTY)
FMS logo
Fresenius Medical Care AG & Co KGaA (FMS)
SOLV logo
Solventum (SOLV)
ITCI logo
Intra-Cellular Therapies (ITCI)
MRNA logo
Moderna (MRNA)
HOLX logo
Hologic (HOLX)
RPRX logo
Royalty Pharma (RPRX)
ILMN logo
Illumina (ILMN)
INCY logo
Incyte (INCY)

FAQ

  • What is the ticker symbol for United Therapeutics?
  • Does United Therapeutics pay dividends?
  • What sector is United Therapeutics in?
  • What industry is United Therapeutics in?
  • What country is United Therapeutics based in?
  • When did United Therapeutics go public?
  • Is United Therapeutics in the S&P 500?
  • Is United Therapeutics in the NASDAQ 100?
  • Is United Therapeutics in the Dow Jones?
  • When was United Therapeutics's last earnings report?
  • When does United Therapeutics report earnings?
  • Should I buy United Therapeutics stock now?

What is the ticker symbol for United Therapeutics?

The ticker symbol for United Therapeutics is NASDAQ:UTHR

Does United Therapeutics pay dividends?

No, United Therapeutics does not pay dividends

What sector is United Therapeutics in?

United Therapeutics is in the Healthcare sector

What industry is United Therapeutics in?

United Therapeutics is in the Biotechnology industry

What country is United Therapeutics based in?

United Therapeutics is headquartered in United States

When did United Therapeutics go public?

United Therapeutics's initial public offering (IPO) was on June 17, 1999

Is United Therapeutics in the S&P 500?

No, United Therapeutics is not included in the S&P 500 index

Is United Therapeutics in the NASDAQ 100?

No, United Therapeutics is not included in the NASDAQ 100 index

Is United Therapeutics in the Dow Jones?

No, United Therapeutics is not included in the Dow Jones index

When was United Therapeutics's last earnings report?

United Therapeutics's most recent earnings report was on Feb 26, 2025

When does United Therapeutics report earnings?

The next expected earnings date for United Therapeutics is May 1, 2025

Should I buy United Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions